RecruitingPhase 2NCT05465954

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mayo Clinic
Principal Investigator
Jian L. Campian, MD, PhD
Mayo Clinic in Rochester
Intervention
Biospecimen Collection(procedure)
Enrollment
54 enrolled
Eligibility
18 years · All sexes
Timeline
20232028

Study locations (1)

Collaborators

NeoImmuneTech · Merck Sharp & Dohme LLC · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05465954 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma

← Back to all trials